drugset / Trial / NCT03938454
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
NaSingle-groupOpen-labelTreatment
Summary
The goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.
Timeline
- Start
- 2019-10-16
- Primary completion
- 2023-03-28
- Completion
- 2023-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizanlizumab | Monoclonal antibody | 5 mg/kg | Intravenous |